Thursday September 11 8:27 AM EDT
Company Press Release
Genta Appoints Donald Drapkin as Director and Chairman
Michael Weiss Is Selected As Vice Chairman
Three Additional New Directors Are Elected
Genta Incorporated (Nasdaq:GNTA) today announced that its Board of Directors has elected a new Chairman: Donald G.
Drapkin, Vice Chairman of MacAndrews & Forbes Holdings, Inc.; Chairman of Cardio Technologies, Inc., and VIMRX
Pharmaceuticals Inc.; and Director of numerous corporations including Revlon, Inc. and The Coleman Company, Inc. Mr.
Drapkin succeeds Michael S. Weiss - Senior Managing Director of Paramount Capital, Inc., and Chairman of Procept Inc. -
who has served as Genta's Chairman on an interim basis. Mr. Weiss will continue to serve on the Genta Board, as Vice
Chairman.
The Board elected the following three new directors in addition to Mr. Drapkin:
Glenn L. Cooper, M.D., who is President and Chief Executive Officer of Interneuron Pharmaceuticals, Inc. Dr.
Cooper is also Chairman and Acting President and CEO of Transcell Technologies, Inc., Chairman of Intercardia, Inc.
and Chairman of Progenitor, Inc. Dr. Cooper was formerly affiliated with Eli Lilly and Company, where he held a
variety of positions in clinical research and regulatory affairs.
Bobby W. Sandage, Jr., Ph.D., who is Executive Vice President, Research and Development, and Chief Scientific
Officer, Interneuron Pharmaceuticals, Inc., and Adjunct Professor Of Pharmacology, Massachusetts College of
Pharmacy. Dr. Sandage formerly held various positions in the Cardiovascular Research and Development division
of DuPont Merck Pharmaceutical Company.
-- Andrew J. Stein, Chairman of the Board, Asia Pacific Holdings Corporation, and Equity Partner in Metromedia Asia. Mr.
Stein was formerly President of the New York City Council and Manhattan Borough President. Mr. Stein was also a
Member of the New York State Assembly where he served on the Health Committee and was appointed by Gov. Nelson
Rockefeller as Chairman of the Commission on Living Costs and the Economy, which reformed the nursing home industry in
New York State.
The Company also announced the resignation of two directors, Paul O. P. Ts'o, Ph.D., and Sharon B. Webster, Ph.D., who
will remain consultants to Genta. Robert E. Klem, Ph.D., will remain a director, bringing the Genta Board of Directors to a
total of six members.
``We want to extend a warm welcome to our new Board members, whose significant professional accomplishments will be of
immense benefit in Genta's continuing development,'' Mr. Weiss stated. ``At the same time, the Board expresses deep
gratitude to Drs. Ts'o and Webster for their many and invaluable contributions. We look forward to their continued counsel
as consultants.''
Genta Incorporated (Nasdaq:GNTA) is a biopharmaceutical company whose strategy consists of building a product and
technology portfolio that represents varying degrees of development risk and market potential, including Anticode(TM)
(antisense) products intended to treat cancer at its genetic source, oral controlled-release drugs and other genomics
opportunities. |
